Penault-Llorca, F., Filleron, T., Asselain, B., Baehner, F. L., Fumoleau, P., Lacroix-Triki, M., . . . Roché, H. (2018). The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial). BMC Cancer.
Chicago Style CitationPenault-Llorca, Frédérique, et al. "The 21-gene Recurrence Score® Assay Predicts Distant Recurrence in Lymph Node-positive, Hormone Receptor-positive, Breast Cancer Patients Treated With Adjuvant Sequential Epirubicin- and Docetaxel-based or Epirubicin-based Chemotherapy (PACS-01 Trial)." BMC Cancer 2018.
Cita MLAPenault-Llorca, Frédérique, et al. "The 21-gene Recurrence Score® Assay Predicts Distant Recurrence in Lymph Node-positive, Hormone Receptor-positive, Breast Cancer Patients Treated With Adjuvant Sequential Epirubicin- and Docetaxel-based or Epirubicin-based Chemotherapy (PACS-01 Trial)." BMC Cancer 2018.